Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals Inc. has announced participation in the upcoming 2024 RBC Capital Markets Global Healthcare Conference in New York, planning to engage in one-on-one investor meetings and a fireside chat. A live webcast of the chat will be accessible via Aurinia’s website. The company, known for introducing LUPKYNIS, the first FDA-approved oral therapy for lupus nephritis, continues to focus on innovative treatments for autoimmune diseases.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
